Merck (NYSE:MRK) - Stock Price, News & Analysis

MRK Stock Overview

Merck & Co., Inc. operates as a healthcare company worldwide.

MRK fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	1/6
Financial Health	3/6
Dividends	4/6

Rewards

Trading at 51.7% below our estimate of its fair value

Earnings are forecast to grow 35.63% per year

Risk Analysis

Dividend of 2.81% is not well covered by earnings

Large one-off items impacting financial results

Significant insider selling over the past 3 months

Has a high level of debt

+ 1 more risk

Merck & Co., Inc. Competitors

Johnson & Johnson

NYSE:JNJ

US$374.1b

Pfizer

NYSE:PFE

US$161.7b

Eli Lilly

NYSE:LLY

US$529.0b

Bristol-Myers Squibb

NYSE:BMY

US$102.1b

Price History & Performance

Summary of all time highs, changes and price drops for Merck
Historical stock prices
Current Share Price	US$103.75
52 Week High	US$119.65
52 Week Low	US$96.36
Beta	0.35
1 Month Change	1.34%
3 Month Change	-4.86%
1 Year Change	-4.62%
3 Year Change	25.06%
5 Year Change	35.66%
Change since IPO	691.73%

Merck (NYSE:MRK) Is Increasing Its Dividend To $0.77

Dec 08

Recent updates

Merck & Co., Inc.'s (NYSE:MRK) Intrinsic Value Is Potentially 92% Above Its Share Price

Oct 16

Merck: Right On Time

Oct 09

Merck: Secure A Safe 8% Annualized Return For The Next Decade

Sep 20

Shareholder Returns

	MRK	US Pharmaceuticals	US Market
7D	0.3%	0.6%	0.2%
1Y	-4.6%	-2.3%	15.9%

Return vs Industry: MRK underperformed the US Pharmaceuticals industry which returned -2.3% over the past year.

Return vs Market: MRK underperformed the US Market which returned 15.9% over the past year.

Price Volatility

Is MRK's price volatile compared to industry and market?
MRK volatility
MRK Average Weekly Movement	2.1%
Pharmaceuticals Industry Average Movement	10.9%
Market Average Movement	6.1%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	2.9%

Stable Share Price: MRK is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: MRK's weekly volatility (2%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1891	68,000	Rob Davis	https://www.merck.com

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Merck & Co., Inc. Fundamentals Summary

How do Merck's earnings and revenue compare to its market cap?
MRK fundamental statistics
Market Cap	US$263.23b
Earnings (TTM)	US$4.61b
Revenue (TTM)	US$59.32b

57.1x

P/E Ratio

4.4x

P/S Ratio

Is MRK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
MRK income statement (TTM)
Revenue	US$59.32b
Cost of Revenue	US$15.96b
Gross Profit	US$43.35b
Other Expenses	US$38.74b
Earnings	US$4.61b

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Feb 01, 2024

Earnings per share (EPS)	1.82
Gross Margin	73.09%
Net Profit Margin	7.77%
Debt/Equity Ratio	84.4%

How did MRK perform over the long term?

See historical performance and comparison

Dividends

2.8%

Current Dividend Yield

159%

Payout Ratio

Does MRK pay a reliable dividends?

See MRK dividend history and benchmarks

When do you need to buy MRK by to receive an upcoming dividend?
Merck dividend dates
Ex Dividend Date	Dec 14 2023
Dividend Pay Date	Jan 08 2024
Days until Ex dividend	4 days
Days until Dividend pay date	29 days

Does MRK pay a reliable dividends?

See MRK dividend history and benchmarks

MRK Stock Overview

Rewards

Risk Analysis

Merck & Co., Inc. Competitors

NYSE:JNJ

US$374.1b

NYSE:PFE

US$161.7b

NYSE:LLY

US$529.0b

NYSE:BMY

US$102.1b

Price History & Performance

Recent News & Updates

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Merck (NYSE:MRK) Is Increasing Its Dividend To $0.77

Upcoming dividend of US$0.77 per share at 2.8% yield

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer

Merck & Co., Inc. Announces Management Changes, Effective on December 4, 2023

Merck & Co., Inc. (NYSE:MRK) entered into definitive agreement to acquire an unknown stake in Caraway Therapeutics, Inc. from AbbVie Ventures, Inc., SV Health Investors, LLC,Dementia Discovery LP, Amgen Ventures and Eisai Innovation Inc. for $610 million.

Recent updates

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Merck (NYSE:MRK) Is Increasing Its Dividend To $0.77

Upcoming dividend of US$0.77 per share at 2.8% yield

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer

Merck & Co., Inc. Announces Management Changes, Effective on December 4, 2023

Merck & Co., Inc. (NYSE:MRK) entered into definitive agreement to acquire an unknown stake in Caraway Therapeutics, Inc. from AbbVie Ventures, Inc., SV Health Investors, LLC,Dementia Discovery LP, Amgen Ventures and Eisai Innovation Inc. for $610 million.

Merck: A Dividend Growth Stock Worth Considering

FDA Approves Merck’s KEYTRUDA (Pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Merck Receives Positive Eu CHMP Opinion for Keytruda (Pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

New minor risk - Insider selling

Insider recently sold US$4.6m worth of stock

Consensus EPS estimates fall by 17%

Merck: Investing In Excellence

These 4 Measures Indicate That Merck (NYSE:MRK) Is Using Debt Reasonably Well

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

Consensus EPS estimates fall by 84%, revenue upgraded

Merck & Co., Inc. Updates Financial Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Merck Announces Results from the Phase 3 LITESPARK-005 Trial Investigating WELIREG

Merck Q3 2023 Earnings Preview: Keytruda LOE Continues To Dominate Narrative

Merck Receives Positive Eu Chmp Opinion for Prevymis® for Prevention of Cmv Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult Hsct Recipients At Risk for Late Cmv Infection and Disease

FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With Resectable (T=4 cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery

Merck & Co., Inc.'s (NYSE:MRK) Intrinsic Value Is Potentially 92% Above Its Share Price

Merck Receives Positive EU CHMP Opinion for KEYTRUDA (Pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS 1)

Merck Announces New Data for Four Approved Medicines and Three Pipeline Candidates in More Than 15 Types of Cancer

Merck: Right On Time

Merck Announces its KEYTRUDA (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients with Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery

Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept

Eisai and Merck Provide Update on Two Phase 3 Trials Evaluating Lenvima Plus Keytruda with Certain Types of Metastatic Non-Small Cell Lung Cancer

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Merck Announces the U.S. Food and Drug Administration (FDA) Has Accepted and Granted Priority Review for A Supplemental New Drug Application (sNDA) Seeking Approval for WELIREG

Merck: Secure A Safe 8% Annualized Return For The Next Decade

Merck Receives Positive Eu Chmp Opinion for Keytruda® (Pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer At High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

Upcoming dividend of US$0.73 per share at 2.7% yield

Merck Announces European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS =1)

Merck and Eisai Provides Update on Phase 3 Leap-010 Trial Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) in Patients with Certain Types of Recurrent or Metastatic Head and Metastatic Head and Neck Squamous Cell Carcinoma

AstraZeneca and Merck Announces Approval in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Shareholder Returns

Price Volatility

About the Company

Merck & Co., Inc. Fundamentals Summary

57.1x

4.4x

Earnings & Revenue

Dividends

2.8%

159%